Vaxil Bio Ltd. (VXL.V)

0.0350 -0.0050 (-12.50%) At close: 03:59PM EDT

Vaxil Bio Ltd.

3400 One First Canadian Place
Toronto, ON M5X 1A4
Canada

https://www.vaxil-bio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA	Chairman & CFO	60k	N/A	1973
Dr. Yuval Avnir Ph.D.	Head of R&D & CEO	N/A	N/A	N/A
Dr. Riva Kovjazin M.D.	Sr. Scientist & Member of Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.

Corporate Governance

Vaxil Bio Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.